Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44ng Trends Data Analysis Biosimilars ernative Medicine Individualized Care Data Analysis Data Analysis 27 MONDAY, SEPTEMBER 18, 2017 Data Analysis MONDAY, SEPTEMBER 18, 2017 Data Analysis l Data Analysis l Data AnalysisSymposium 10 Data AnalysisSymposium 10 Data Analysis l 1:30 – 5:30 pm Challenges & Opportunities in the Development of Inhaled Medicines DISCOVERY TRACK Offers both CME and CPE Credit UAN #0238-0000-17-014-L05-P ACPE – 3.5 CONTACT HOURS/APPLICATION-BASED CO-CHAIRS: Clive Page, BSc, PhD, Professor of Pharmacology, Sackler Inst of Pulmonary Pharmacology, King’s Coll Anne Lexmond, PharmD, PhD, Dept of Pharmaceutical Technology & Biopharmacy, Univ of Groningen TARGET AUDIENCE: This Symposium will be useful for clinical pharmacologists specializing in respiratory medicine, respiratory drug developers and researchers, both academic and industrial, regulators and respiratory physicians. GOALS AND OBJECTIVES: Following completion of this activity, the learner will be able to: 1. Assess technical specifications of inhalation devices in relation to the purpose of the drug and the patient for whom the drug is intended; 2. Apply the principles of how to provide tailored inhaled drug therapy to the individual patient; 3. Identify emerging therapeutic opportunities for inhaled drug delivery; 4. Review the major issues facing the development of inhaled medicines. 1:30 – 1:35 pm Introduction Clive Page, BSc, PhD, Professor of Pharmacology, Sackler Inst of Pulmonary Pharmacology, King’s Coll 1:35 – 1:55 pm Pharmacokinetics & Bioequivalence Testing of Orally-inhaled Steroids Hartmut Derendorf, PhD, Distinguished Professor & Chair, Univ of Florida 1:55 – 2:15 pm Pulmonary Absorption & Bioavailability of Inhaled Products Günther Hochhaus, PhD, Professor, Univ of Florida 2:15 – 2:50 pm Target Populations & Inhalation Device Choices Beth Laube, PhD, Professor, Pediatrics, Johns Hopkins Univ 2:50 – 3:25 pm Beyond Asthma & COPD: Aerosol Delivery of Drugs for Cancer Treatment & Prevention Steven Belinsky, PhD, Vice President, Academic Research & Senior Scientist, Lovelace Respiratory Research Inst 3:25 – 3:55 pm / Break 3:55 – 4:30 pm Foamy Macrophages: What Do They Really Mean for the Safety of Inhaled Medicines? Ben Forbes, PhD, Professor, King’s Coll London 4:30 – 5:05 pm Opportunities & Challenges Facing the Development of Inhaled Medicines Bavna Saluja, PhD, Reviewer, Office of Clinical Pharmacology, Div of Clinical Pharmacology 2, US Food & Drug Administration 5:05 – 5:30 pm Panel Discussion Symposia